Mirabegron Glenmark

Mirabegron, the active ingredient in Mirabegron Glenmark, is a β3‑adrenergic receptor agonist presented as a tablet for oral use. It treats overactive bladder symptoms, including urinary urgency and frequency, in adult patients.

GNH USA supplies Mirabegron Glenmark as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirabegron is indicated for conditions affecting bladder storage function within the overactive bladder disease family. - Overactive bladder: reduces urgency and frequency, increasing functional bladder capacity. - Urinary urgency: lessens the sudden, compelling need to void. - Urinary frequency: decreases the number of voids during the day.

Adverse reactions may occur with Mirabegron therapy.

Common Side Effects: - Hypertension: elevated blood pressure observed in some patients. - Nasopharyngitis: mild upper respiratory tract infection symptoms. - Headache: intermittent mild to moderate head pain. - Constipation: reduced bowel motility. - Dry mouth: decreased salivation. - Urinary retention: difficulty initiating or completing voiding.

Serious or Rare Side Effects: - Severe hypertension: markedly high blood pressure requiring medical intervention. - Acute urinary retention: sudden inability to urinate, potentially needing catheterisation. - Cardiovascular events: chest pain or arrhythmia. - Angioedema: swelling of face, lips, or throat. - Allergic reactions: rash, pruritus, or anaphylaxis. - QT interval prolongation: rare cardiac conduction abnormality.

Before initiating Mirabegron, clinicians should consider several safety measures. - Blood pressure monitoring: check baseline and periodic readings. - Urinary retention assessment: evaluate for pre‑existing retention. - Renal and hepatic function: adjust use if impairment is present. - Concomitant antihypertensives: review to avoid excessive blood pressure lowering. - Uncontrolled hypertension: avoid use in patients with markedly elevated pressure. - Store at ambient temperature: keep in the original pack, protect from moisture.

Mirabegron can affect the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid): - Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): may increase Mirabegron exposure. - Potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): can raise plasma levels. - Other β3‑adrenergic agonists: additive bladder‑relaxant effect.

Moderate Interactions (Monitor Closely): - CYP2D6 substrates (e.g., metoprolol, tamoxifen): may have altered clearance. - CYP3A4 substrates (e.g., midazolam, calcium channel blockers): monitor for increased effects. - Diuretics: concurrent use may heighten risk of hypertension.